Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

961. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. (PubMed)

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Insulin-like growth factor (IGF)-I and its main binding protein, IGFBP-3, modulate cell growth and survival, and are thought to be important in tumour development. Circulating concentrations of IGF-I might be associated with an increased risk of cancer, whereas IGFBP-3 concentrations could be associated with a decreased cancer risk.We did a systematic review and meta

2004 Lancet

962. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. (PubMed)

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. Insulin resistance appears to be the best predictor of the development of diabetes in the children of patients with type 2 diabetes, but the mechanism responsible is unknown.We performed hyperinsulinemic-euglycemic clamp studies in combination with infusions of [6,6-(2)H(2)]glucose in healthy, young, lean, insulin-resistant offspring of patients with type 2 diabetes and insulin-sensitive control (...) subjects matched for age, height, weight, and physical activity to assess the sensitivity of liver and muscle to insulin. Proton ((1)H) magnetic resonance spectroscopy studies were performed to measure intramyocellular lipid and intrahepatic triglyceride content. Rates of whole-body and subcutaneous fat lipolysis were assessed by measuring the rates of [(2)H(5)]glycerol turnover in combination with microdialysis measurements of glycerol release from subcutaneous fat. We performed (31)P magnetic

Full Text available with Trip Pro

2004 NEJM

963. Insulinomas and expression of an insulin splice variant. (PubMed)

Insulinomas and expression of an insulin splice variant. Insulinomas are beta-cell tumours characterised by uncontrolled insulin secretion even in the presence of hypoglycaemia. However, the mechanisms allowing such excessive insulin secretion are not known. Insulin secretion can occur only when the beta-cell insulin stores have been replenished by insulin biosynthesis, which is mainly controlled by translation. Such specific translational regulation often involves the 5' untranslated region (...) . We have identified an insulin splice variant in isolated human pancreatic islets of non-diabetic donors that retains 26 bp of intron 1 and thereby changes the 5' untranslated region, but leaves the coding region unchanged. This splice variant has increased translation efficiency in vitro and in vivo compared with native insulin mRNA. However, splice variant expression is less than 1% of native insulin mRNA in normal islets.To test whether this splice variant is involved in insulin production

2004 Lancet

964. [Effect of a two-week program of individually monitored physical activity on insulin resistance in obese non-insulin-dependent diabetics]. (PubMed)

[Effect of a two-week program of individually monitored physical activity on insulin resistance in obese non-insulin-dependent diabetics]. It is well known that under the influence of regular, individually measured aerobic physical activity, it is possible to raise the biological efficiency of insulin by several mechanisms: by increasing the number of insulin receptors, their sensitivity and efficiency, as well as by increasing glucose transporters GLUT-4 on the level of cell membrane. The aim (...) of this research was to examine whether decreased insulin resistance could be achieved under the influence of the program of individually measured aerobic physical activity in the 2-week period, in the obese type 2 diabetes patients with the increased aerobic capacity (VO2)max. In 10 type 2 diabetes patients 47.6 +/- 4.6 years of age (group E), in the 14-days period, program of aerobic training was applied (10 sessions--35 min session of walking on treadmill, intensity 60.8 +/- 5.7% (VO2)max, frequency 5 times

2004 Vojnosanitetski pregled

965. Glucose-insulin-potassium in cardiac surgery: a meta-analysis

Glucose-insulin-potassium in cardiac surgery: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

966. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials

Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

967. BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes

BPG for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes Best Practice Guideline for the Subcutaneous Administration of Insulin in Adults with Type 2 Diabetes Nursing Best Practice Guideline Shaping the future of Nursing June 2004Greetings from Doris Grinspun Executive Director Registered Nurses Association of Ontario It is with great excitement that the Registered Nurses Association of Ontario (RNAO) disseminates this nursing best practice guideline to you. Evidence (...) Administration of Insulin in Adults with Type 2 Diabetes Guideline Development Panel Members Declarations of interest and confidentiality were made by all members of the guideline development panel. Further details are available from the Registered Nurses Association of Ontario. Anna Brundage, RN, BHSc(N), CDE Team Leader Manager TRIDEC Sunnybrook and Women’s College Health Sciences Centre Toronto, Ontario Ceilia Ayotte, RN, CDE Diabetes Educator Peterborough Regional Health Centre Peterborough, Ontario

2004 Registered Nurses' Association of Ontario

968. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technology Assessment 2004; 8(43): 1-186 Authors' objectives This systematic review examines the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) using insulin pumps compared with multiple daily injections (MDI) for diabetes. Authors' conclusions When compared with optimised MDI, CSII results

2004 Health Technology Assessment (HTA) Database.

969. Insulin glargine for type 2 diabetes

Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Insulin glargine for type 2 diabetes Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Insulin glargine for type 2 diabetes. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of insulin glargine (Trade Mark: Lantus) - a biosynthetic, long-acting human insulin analogue - to treat type 2 diabetes. Authors' conclusions Patients who have adequate glycemic control and minimal hypoglycemic events with NPH insulin will likely not derive additional benefit from insulin glargine (in most studies, insulin glargine did not significantly reduce fasting

2004 Health Technology Assessment (HTA) Database.

970. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Warren E, Weatherley-Jones E, Chilcott J, Beverley C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technology Assessment 2004; 8(45): 1-72 Authors' objectives The aim of this review was to evaluate the use of insulin glargine in its licensed basal-bolus indication in terms of both clinical and cost-effectiveness. Authors' conclusions The evidence suggests that, compared with NPH insulin, insulin

2004 Health Technology Assessment (HTA) Database.

971. Insulin detemir for diabetes mellitus

Insulin detemir for diabetes mellitus Insulin detemir for diabetes mellitus Insulin detemir for diabetes mellitus Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment. Insulin detemir for diabetes mellitus. Ottawa (...) : Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of insulin detemir (Trade Name: Levemir, manufactured by Novo Nordisk) for the management of type 1 (insulin dependent) diabetes mellitus (DM) and type 2 (non-insulin dependent) DM. Authors' conclusions Insulin detemir is a new long-acting insulin analogue for the treatment of type 1 and type 2 DM. It does not improve HbA1c control or reduce overall

2004 Health Technology Assessment (HTA) Database.

972. Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications

Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Diabetes mellitus treatment with insulin pump: clinical effectiveness - indications. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives This study aims to summarise the available evidence on insulin pumb treatment of diabetes mellitus. Authors' conclusions CSII represents a higher cost in diabetes type 1

2004 Health Technology Assessment (HTA) Database.

973. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes

Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes Cote B, St-Hilaire C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Cote B, St-Hilaire C. Comparison of the insulin pump and multiple daily insulin injections in intensive therapy for type 1 diabetes. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 04-07. 2004 Authors' objectives This report examines the safety, efficacy and cost-effectiveness of the insulin pump compared to multiple daily insulin injections for the treatment of type 1 diabetes, a chronic

2004 Health Technology Assessment (HTA) Database.

974. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK

Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK Shearer A, Bagust A, Sanderson D, Heller S, Roberts S Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A structured treatment and teaching programme (STTP), combining dietary freedom with insulin adjustment for Type 1 diabetes, was evaluated. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population

2004 NHS Economic Evaluation Database.

975. Insulin aspart: an evidence-based medicine review

Insulin aspart: an evidence-based medicine review Insulin aspart: an evidence-based medicine review Insulin aspart: an evidence-based medicine review Haycox A CRD summary Evidence on the efficacy, safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin, in diabetes mellitus, was reviewed. The review concluded that there is evidence to support the efficacy, tolerability and ease of administration of insulin aspart. However (...) , it is difficult to assess the reliability of this conclusion. Authors' objectives To review and evaluate the published evidence on the efficacy, safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI), in diabetes mellitus. Searching The Cochrane Library, BIOSIS Previews, EMBASE-DP and MEDLINE were searched; the search period was not reported. The search was restricted to publications in the English language. Study selection Study designs

2004 DARE.

976. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes Colquitt J L, Green C, Sidhu M K, Hartwell D, Waugh N CRD summary This review investigated the clinical effectiveness and cost-effectiveness of insulin treatment for diabetes, by comparing continuous subcutaneous insulin infusion (...) (from a pump) with multiple daily injections. It concluded that continuous infusion treatment resulted in a modest improvement in glycated haemoglobin levels in adults with type 1 diabetes. This was a well-conducted review and most of the conclusions are justified. Authors' objectives To assess the clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) using insulin pumps, compared with intensive treatment with multiple daily injections (MDI

2004 DARE.

977. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine Warren E, Weatherley-Jones E, Chilcott J, Beverley C CRD summary This review concluded there was some evidence that insulin glargine was more effective than once-daily neutral protamine Hagedorn in reducing nocturnal (...) hypoglycaemia incidence, but there was no evidence of long-term glycaemic control improvement. The review methodology was poorly reported and the available data were limited, but the authors' cautious conclusions reflect the data presented and are likely to be reliable. Authors' objectives To assess the incremental clinical and cost-effectiveness of basal-bolus insulin glargine, a long-acting insulin analogue, compared with existing basal-bolus insulin treatments. Searching The following databases were

2004 DARE.

978. Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes

Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Improved perioperative glycemic control by continuous insulin infusion under supervision of an endocrinologist does not increase costs in patients with diabetes Vora A C, Saleem (...) T M, Polomano R C, Eddinger V L, Hollenbeak C S, Girdharry D T, Joshi R, Martin D, Gabbay R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors assessed an insulin infusion glycaemic control protocol (IGCP

2004 NHS Economic Evaluation Database.

979. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. (PubMed)

Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Dehydroepiandrosterone (DHEA) administration has been shown to reduce accumulation of abdominal visceral fat and protect against insulin resistance in laboratory animals, but it is not known whether DHEA decreases abdominal obesity in humans. DHEA is widely available as a dietary supplement without a prescription.To determine whether DHEA replacement therapy decreases abdominal fat (...) and improves insulin action in elderly persons.Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from June 2001 to February 2004.Fifty-six elderly persons (28 women and 28 men aged 71 [range, 65-78] years) with age-related decrease in DHEA level.Participants were randomly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months.The primary outcome measures were 6-month change in visceral and subcutaneous abdominal fat measured by magnetic

Full Text available with Trip Pro

2004 JAMA Controlled trial quality: predicted high

980. Use of metabolic markers to identify overweight individuals who are insulin resistant. (PubMed)

Use of metabolic markers to identify overweight individuals who are insulin resistant. Insulin resistance is more common in overweight individuals and is associated with increased risk for type 2 diabetes mellitus and cardiovascular disease. Given the current epidemic of obesity and the fact that lifestyle interventions, such as weight loss and exercise, decrease insulin resistance, a relatively simple means to identify overweight individuals who are insulin resistant would be clinically (...) useful.To evaluate the ability of metabolic markers associated with insulin resistance and increased risk for cardiovascular disease to identify the subset of overweight individuals who are insulin resistant.Cross-sectional study.General clinical research center.258 nondiabetic, overweight volunteers.Body mass index; fasting glucose, insulin, lipid and lipoprotein concentrations; and insulin-mediated glucose disposal as quantified by the steady-state plasma glucose concentration during the insulin

2003 Annals of Internal Medicine